


**Amendments to the Claims**

This claim listing will replace all prior versions of claims and claim listings in the application:

WE CLAIM:

1. (Previously presented) A compound structurally represented by Formula I






Formula (I)

or pharmaceutically acceptable salts thereof wherein:

R<sup>1</sup> is

-CH<sub>2</sub>N R<sup>3</sup>R<sup>4</sup>,

-CONR<sup>3</sup>R<sup>4</sup>,



R<sup>2</sup> is



-Hydrogen,


-NH-(C<sub>1</sub>-C<sub>6</sub>) alkyl,

-NH-(C<sub>1</sub>-C<sub>4</sub>) alkylene-phenyl,

-NH(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

-NR<sup>3</sup>R<sup>4</sup>,





wherein;

$R^3$  is hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

$R^4$  is

-(C<sub>1</sub>-C<sub>4</sub>) alkyl,

-(C<sub>1</sub>-C<sub>4</sub>) alkylene -phenyl,

wherein  $R^3$  and  $R^4$  can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen,  $R^3$ , and  $R^4$ , is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by  $R^5$ , and


$R^5$  is hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>) alkyl, wherein optionally  $R^5$  forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C<sub>1</sub>-C<sub>4</sub>) alkylene -N-pyrrolidinyl,





-(C<sub>1</sub>-C<sub>4</sub>) alkylene -N- piperidinyl;






provided that when  $R^1$  is  $-\text{CH}_2\text{N} R^3 R^4$  or  $-\text{CONR}^3 R^4$ , then  $R^2$  is








2. (Canceled)
3. (Original) The compound of claim 1, wherein  $R^1$  is  $\text{CONR}^3 R^4$ , and  $R^3$  and  $R^4$  cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by  $-\text{CH}_2-$  pyrrolidinyl.
4. (Original) The compound of claim 1, wherein  $R^1$  is  $\text{CH}_2\text{NR}^3 R^4$ , and  $R^3$  and  $R^4$  cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by  $-\text{CH}_2-$  pyrrolidinyl.
5. (Original) The compound of claim 3 wherein  $R^2$  is  $\text{N} R^3 R^4$ , and  $R^3$  and  $R^4$  cyclize to form, together with the nitrogen to which they are attached, a five membered ring.

6. (Original) The compound of claim 4 wherein R<sup>2</sup> is N R<sup>3</sup>R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
7. (Previously presented) The compound of claim 1, further represented by any one of the formula selected from the group consisting of:

Example Number	
1	
2	
3	
4	




5	
6	
8	
9	
13	


14	
15	
16	
17	
18	

or a pharmaceutically acceptable salt thereof.

8. (Previously presented) A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
9. (Canceled)
10. (Canceled)
11. (Previously presented) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 1.

12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Withdrawn) A compound selected from the group consisting of:

Example Number	
7	
10	
11	



or a pharmaceutically acceptable salt thereof.